Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aurinia Pharmaceuticals Inc - Common Shares (NQ:AUPH)

12.12 -0.10 (-0.82%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Aurinia Pharmaceuticals Inc - Common Shares

< Previous 1 2 3 4 5 6 Next >
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Shows Strong Growth Traits in Fundamental Analysis
Discover Aurinia Pharmaceuticals (AUPH), a top growth stock with explosive earnings, soaring revenue, and high ROE, using Louis Navellier's proven investment strategy. 
Via Chartmill
Aurinia Pharma Stands By Lupus Drug After FDA Official’s Retracted Post Sparks 16% Selloff — Retail Stays Bullish On Recovery
Via Stocktwits
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers SciSparc (NASDAQ: SPRC) shares increased by 28.2% to $5.68 during Monday's after-market session. The company's market cap stands at $2.2 million. 
Via Benzinga
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Passes Louis Navellier's Growth Screen
Aurinia Pharmaceuticals (AUPH) is a top growth stock pick based on Louis Navellier's strategy, showing explosive earnings growth, strong sales momentum, and rising profit margins. 
Via Chartmill
United Therapeutics Price Strength Rating Jumps After Its Stock Soared 33% Last Week On Positive Drug Test Results
United Therapeutics also boasts a terrific 96 Composite Rating. The Composite score combines five separate proprietary ratings into one. 
Via Investor's Business Daily
Topics ETFs
Earnings Scheduled For July 31, 2025
 
Via Benzinga
Earnings Scheduled For May 12, 2025
 
Via Benzinga
Earnings Scheduled For February 27, 2025
 
Via Benzinga
Earnings Scheduled For February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Shows Strong Growth Metrics and Earnings Momentum
Aurinia Pharma (AUPH) shows strong growth momentum with surging earnings, impressive sales growth, and major margin expansion, making it a top pick for growth investors. 
Via Chartmill
Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded
Additionally, the IBD SmartSelect Composite Rating for Argenx stock rose from 94 to a near best 96 Tuesday. 
Via Investor's Business Daily
Topics ETFs
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Fits Louis Navellier’s High-Growth Stock Criteria
Louis Navellier's growth strategy highlights Aurinia Pharmaceuticals (AUPH) for strong earnings momentum, rising revenue, and solid ROE—key traits for high-growth stock success. 
Via Chartmill
Gilead Sciences Reports Earnings Thursday. Can The Highly Ranked Drugmaker Beat Its 237% Profit Surge Last Quarter?
The upgraded score means Gilead is now outperforming 96% of all stocks in terms of the most important stock-picking criteria. 
Via Investor's Business Daily
Aurinia (AUPH) Q2 Revenue Jumps 22%
Via The Motley Fool
Topics Intellectual Property
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) – A Strong Candidate for Growth Investors
Aurinia Pharmaceuticals (AUPH) meets key growth criteria from Louis Navellier’s strategy, with strong earnings, sales growth, and improving margins. The stock shows solid financial health and... 
Via Chartmill
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) – A Strong Candidate for Growth Investors
Aurinia Pharmaceuticals (NASDAQ:AUPH) shows strong growth metrics, including surging earnings, revenue, and cash flow, making it a candidate for investors following Louis Navellier’s strategy. 
Via Chartmill
Retail Bulls Charge Into Aurinia Pharmaceuticals Ahead Of Autoimmune Trial Results
AUR200 targets both BAFF and APRIL, which are key immune system proteins. It is being developed for one large indication and one rare disease. 
Via Stocktwits
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) – A Strong Candidate for Growth Investors
Aurinia Pharmaceuticals (AUPH) shows strong growth, earnings momentum, and improving margins, making it a candidate for investors following Louis Navellier’s strategy. 
Via Chartmill
US Stocks Likely To Open On A Mixed Note: 'Nothing Good Happens Above A 5% Yield,' Says Expert
U.S. stock futures were fluctuating on Friday after a mixed close on Thursday. Futures of benchmark indices were mixed in premarket. 
Via Benzinga
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) – A Strong Candidate for Growth Investors
Aurinia Pharmaceuticals (AUPH) meets Louis Navellier’s growth criteria with strong earnings surprises, accelerating revenue, and improving margins. A solid pick for growth-focused investors. 
Via Chartmill
Aurinia Pharma Swings Into Profit As Q1 Sales Jumps 24%, Sticks To Guidance
Aurinia posts Q1 profit and 25% LUPKYNIS sales growth, reports $62.47 million revenue, and reaffirms full-year guidance. 
Via Benzinga
Aurinia Stock Rallies On Upbeat Q1 Earnings, CEO Expects Strong Performance in 2025: Retail Sentiment Brightens
The company also reiterated its full-year total revenue guidance of $250 million to $260 million and net product sales guidance of $240 million to $250 million. 
Via Stocktwits
Uncovering Potential: Aurinia Pharmaceuticals's Earnings Preview
 
Via Benzinga
Is AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) following the Minervini trend for explosive growth?
Should you consider AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) for high growth investing? A fundamental and technical analysis of (NASDAQ:AUPH). 
Via Chartmill
Mainz Biomed Vs. Aurinia Pharma: Retail Traders Weigh In On The Better Biotech Bet
Over the past three months, Mainz has seen a staggering 2,500% increase in message volume on Stocktwits, while Aurinia’s engagement has grown just 23%. 
Via Stocktwits
Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations
Aurinia Pharmaceuticals reported Q4 earnings of 1 cent per share, beating estimates, with LUPKYNIS sales up 36%. 
Via Benzinga
AUPH Stock Earnings: Aurinia Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
AUPH stock results show that Aurinia Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Aurinia Pharmaceuticals Finds No Buyer After Strategic Business Review, Launches Stock Buyback
Aurinia Pharmaceuticals Q4 2023 results: EPS loss $(0.19), sales $45.1 million. AUR200 development halted. Strategic review concludes. $150 million share buyback initiated. 
Via Benzinga
Why Herbalife Shares Are Trading Lower By Around 36%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Herbalife Ltd. (NYSE: HLF) fell sharply in today’s session following weak quarterly earnings. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.